Kairos Pharma Receives Department of Defense Grant to Advance Lung Cancer Biomarker Research

Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has received a Department of Defense grant to further its groundbreaking research in lung cancer treatment. The funding will support the company's ongoing efforts to develop innovative therapeutic approaches that address critical challenges in cancer treatment, particularly drug resistance and immune suppression.

The company is currently advancing two significant clinical trials for its lead candidate ENV105, which targets CD105, a protein identified as a key driver of treatment resistance across multiple cancer types. The trials focus on castrate-resistant prostate cancer and EGFR-dependent non-small cell lung cancer, with anticipated safety and interim efficacy results expected in the second quarter of 2025.

ENV105 represents a novel approach to cancer treatment by targeting CD105, a protein that becomes elevated in response to standard therapies and contributes to treatment resistance. By addressing this mechanism, the therapeutic candidate aims to restore the effectiveness of existing cancer treatments and potentially improve patient outcomes.

In addition to ENV105, Kairos is developing KROS101, an immune response modulator that has recently presented data at key oncology conferences. The company's strategic approach leverages structural biology to overcome significant challenges in cancer treatment, positioning it as an innovative player in the oncological research landscape.

The Department of Defense grant provides critical non-dilutive funding that supports Kairos Pharma's research and development efforts. This financial support, combined with expanding clinical trial networks and analyst coverage from firms like EF Hutton and HC Wainwright, underscores the potential significance of the company's research.

With a robust intellectual property portfolio extending into the 2030s, Kairos Pharma is poised to make meaningful contributions to cancer treatment. The company's focus on addressing drug resistance and immune suppression could potentially transform approaches to treating complex cancer types, offering hope for patients facing challenging therapeutic scenarios.